• P-ISSN 2394-9481 E-ISSN 2394-949X
  • Before December 2023, article status/review can be accessed using old submissions tab

Journal of Medical Sciences and Health

Journal of Medical Sciences and Health

Year: 2024, Volume: 10, Issue: 2, Pages: 204-212

Review Article

Decoding Diabetic Kidney Disease: In-Depth Analysis of Prevalence, Risk Factors, Biomarkers, and Management Strategies

Received Date:10 June 2024, Accepted Date:16 July 2024, Published Date:29 July 2024

Abstract

End-stage kidney disease (ESKD) is primarily caused by diabetic kidney disease (DKD), a common ailment that affects people all over the world and results from diabetes mellitus. Hemodynamic, metabolic, and inflammatory factors interact to influence its development. However, these changes are not unique to DKD, necessitating the development of novel biomarkers to support diagnosis, tracking, evaluation of treatment efficacy, and outcome prediction. High blood sugar levels trigger the disease by increasing the production of reactive oxygen species. Despite its significance as a global medical condition, people often ignore it. DKD causes major challenges for the community, finances, and individuals. Symptoms often remain unnoticed until they become evident, resulting in significant consequences. The absence of detailed data and infrequent screening protocols impede the early identification of diabetic kidney disease (DKD). The right medications and a precise diagnosis could help regulate the illness, prolong life, and lessen the psychological and financial burden on those affected. DKD frequently emerges right after the condition becomes severe. This research aims to identify global cases, factors that heighten the risk of developing DKD, and potential indicators for early diagnosis of DKD.

Keywords: Diabetes mellitus (DM), Diabetic kidney disease (DKD), Epidemiology, Prevalence, Biomarkers, Diagnosis, Management

Introduction

This article examines the inflammatory aspect of diabetic kidney disease (DKD) and the potential use of new biomarkers in DKD treatment 1 . It highlights the importance of early identification of inflammatory biomarkers for minimizing consequences and maximizing treatment choices 2 .

Diabetic nephropathy, also known as diabetic kidney disease (DKD), is a unique condition-affecting individuals with both diabetes and chronic kidney disease 3 , altering the kidney's function and altering the body's waste and fluid elimination. The symptoms of this condition are albuminuria, edema, polyuria, nausea, anemia, and hypertension 4 .

The condition escalates the chance of death by 31.1% in individuals who have diabetes, and this risk amplifies as the seriousness of the disease progresses 5 . Timely identification of DKD is essential in order to mitigate the impact on both individuals and the economy. Nevertheless, it often goes unnoticed until significant issues arise.

Implementing early detection methods is a financially efficient strategy to lessen the overall impact. This research focuses on the worldwide incidence, risk factors, and potential early indications of DKD. 6

Epidemiology and Perspectives in DKD

Diabetes mellitus affects 10.5% of people aged 20-79 globally, with 537 million cases reported in 2021 and projected to reach 643 million by 2030 7 . The disease often takes 4-7 years to diagnose, and clinical damage often does not manifest until later 8 .

The development and advancement of this illness include several factors, including hemodynamic, metabolic, and inflammatory processes. The inflammatory axis is becoming a crucial target for therapeutic intervention 9 .

In China, 38.8% of individuals diagnosed with diabetes had DKD, while 2.9% had it in rural dwellers 10 . In India, 34.4% had DKD, and 62.3% had it in a multicenter study 11 . The older population in the eastern Mediterranean has the highest rates of diabetes mellitus and CKD-DM. In Japan, 15.3% of patients with type 2 diabetes had a poor estimated glomerular filtration rate 12 . In the UK, 28% of patients had renal impairment after a 15-year follow-up period. In the United States, 2.2% of the population has DKD, and the prevalence is rising in direct correlation with diabetes occurrence 13 . The research emphasizes that in order to overcome DKD, there is a need for more awareness and preventative efforts.

Diabetic Kidney Disease (DKD) is a prevalent global health issue, with an estimated incidence of 1.75 in people with diabetes 14 . Research conducted in China, India, and the United Arab Emirates reveals varying incidences of DKD.

Pathophysiology of DKD

The etiology of diabetic kidney disease (DKD) involves a multifactorial interaction of inflammatory, hemodynamic, and metabolic variables 15 . Hyperglycemia sets off a series of metabolic reactions that result in endothelial dysfunction, oxidative stress, and damage to the tubules and glomerulus 16 . Tubular dysfunction affects the processes of reabsorption and secretion, whereas renal hyperfiltration and elevated intraglomerular pressure lead to glomerular damage 17 . Renal injury is further aggravated by chronic inflammation and fibrosis, which leads to a steady loss in kidney function 12 . Comprehending these pathophysiological pathways is essential for creating tailored treatments meant to maintain renal function and enhance DKD outcomes.

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/29ae298d-1af6-43a8-8118-5ad2c4548b02image1.png
Figure 1: 1,2 The Pathophysiology of Diabetic Kidney Disease

Table 1 provides a comprehensive overview of the various factors that contribute to the development and progression of DKD, emphasizing the need for comprehensive management strategies. 18

Table 1: Comprehensive overview of the various factors that contribute to the development and progression of DKD

Sr.No

Contributors

Description

1

Hyperglycemia

Elevated blood glucose levels leading to metabolic changes and kidney damage

2

Hypertension

High blood pressure contributing to renal microvascular damage

3

Dyslipidemia

Abnormal lipid metabolism leading to endothelial dysfunction and renal injury

4

Genetic Predisposition

Inherited susceptibility to kidney disease in individuals with diabetes

5

Inflammation

Chronic low-grade inflammation exacerbating renal damage

6

Oxidative Stress

Imbalance between reactive oxygen species (ROS) and antioxidant defenses

7

Renin-Angiotensin System Activation

Over-activation of the renin-angiotensin system leading to vasoconstriction and fibrosis

8

Protein Kinase C Activation

Dysregulation of protein kinase C signaling pathways contributing to renal injury

9

Advanced Glycation End Products (AGEs)

Accumulation of AGEs leading to endothelial dysfunction and inflammation

10

Renal Hyperfiltration

Increased glomerular filtration rate resulting in glomerular damage

11

Endothelial Dysfunction

Impaired endothelial function contributing to vascular pathology

12

Podocyte Injury

Damage to podocytes disrupting glomerular filtration barrier

13

Tubulointerstitial Fibrosis

Accumulation of extracellular matrix proteins leading to renal fibrosis

14

Autoimmunity

Immune-mediated injury to renal tissue in susceptible individuals

15

Environmental Factors

Lifestyle, diet, and other environmental factors influencing disease progression

The metabolic route encompasses the use of polyol, hexosamine, advanced glycation end products, and protein kinase C 19 . Hyperglycemia leads to kidney injury by forming glycosylated end products, activating protein kinase C, and synthesizing diacylglycerol 20 .

Limitations of Conventional Biomarkers

Albuminuria and a decrease in the estimated glomerular filtration rate (eGFR), which is determined by blood creatinine levels, are diagnostic indications of diabetic kidney disease (DKD). 21 Albuminuria is a reliable biomarker for predicting future progression and evaluating treatment efficacy. Urinary albumin excretion (UAE) is used for risk stratification and measures the extent of albuminuria, making it a crucial tool in diagnosing and managing DKD 22.

Glomerular filtration rate (GFR) is the primary clinical biomarker used to evaluate the prognosis of diabetic kidney disease (DKD) during follow-up. When glomerular filtration rate falls, there is a clear correlation between structural damage and kidney function, but this association is less apparent with mild albuminuria or a slight decline in eGFR 23.

Changes in the present and prior estimated GFRs (eGFRs) are important indicators of how the illness is likely to proceed. The glomerular filtration rate (GFR) is often estimated using the CKD-EPI and MDRD equations. 24 However, it is important to note that these equations have the potential to either underestimate or overestimate the actual GFR. This discrepancy may occur because of compensatory adjustments in the functioning of the remaining nephrons 25. Particularly for those with the common normoalbuminuric phenotype who lack particular therapy options, the diagnostic and follow-up techniques already in use have drawbacks. 26

The research highlights the need for novel biomarkers to improve diagnostic and monitoring methods for diabetic kidney disease, focusing on their effectiveness in diagnosing, monitoring progression, assessing treatment response, and predicting prognosis. 27 The study will investigate the practical application of new biomarkers, as illustrated in Figure 2.

Figure 2 shows tables that provide comprehensive list of overview of conventional biomarkers 2829 vs novel biomarkers 303132 commonly used in clinical practice to diagnose, monitor, and manage Diabetic Kidney Disease, focusing on kidney function, damage, and overall metabolic control.

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ee6d0f47-cdf9-4b85-acdd-5bf8a64310dc/image/7c2ac593-6432-4de4-9dfa-c93584cb9f93-uimage.png
Figure 2: 1,2 This table provides acomprehensive list of overview of Conventional biomarkers 2829 vs novelbiomarkers 303132 commonly used in clinical practice to diagnose, monitor, and manage DiabeticKidney Disease, focusing on kidney function, damage, and overall metabolic control.

Novel Biomarkers in Diabetic Kidney Disease

Early detection is crucial for managing diabetes-related kidney disease, but traditional diagnostic techniques often lead to delayed diagnosis 33. The study of DKD pathophysiology and mechanisms has heightened the importance of discovering novel biomarkers in urine and serum through proteomics and metabolomics.

Advancements in kidney damage knowledge have led to the development of biomarkers that can aid in diagnosing diabetic kidney disease (DKD). These biomarkers, unlike conventional ones like serum creatinine, can enhance the accuracy of DKD assessments, making them more precise tools for evaluating kidney function 34 .

The AKI agreement asserts that biomarkers should not replace conventional testing and clinical evaluations but rather serve as supplementary examinations to identify individuals who can benefit from cardiovascular risk prevention and management strategies 35 .

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/29ae298d-1af6-43a8-8118-5ad2c4548b02image3.jpeg
Figure 3: 1,2 Potential Risk factors of DKD 3637

Biomarkers for the early diagnosis of DKD

Biomarkers like urine albumin excretion rate, UAER, UACR, and eGFR help detect renal damage before clinical signs of diabetic kidney disease (DKD) 6 . New biomarkers like L-FABP, NGAL, and KIM-1 show promise in early detection of renal damage. Integrating these indicators into clinical practice can help mitigate DKD development and related consequences through early intervention and individualized care techniques.

Timely identification and suitable therapies are vital for effectively treating kidney disease (DKD), as they may effectively slow down the course of the illness, enhance life expectancy, and alleviate the physical, emotional, and financial strain associated with it 38 . The absence of diagnostic indicators, such as albuminuria and serum creatinine, poses a hindrance to the timely detection of a condition 39 . Research has shown that albuminuria is an unreliable and insensitive indicator, while serum creatinine does not possess strong predictive capability 40 . Hence, new biomarkers are needed for early diagnosis and treatment of DKD due to their sensitivity and predictability, as existing biomarkers are not very sensitive.

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/29ae298d-1af6-43a8-8118-5ad2c4548b02image4.png
Figure 4: 1,2 Potential Biomarkers for the early diagnosis of DKD 414243

Diagnosis of DKD

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/29ae298d-1af6-43a8-8118-5ad2c4548b02image5.png
Figure 5: Type of biomarker are more important for disease diagnosis and treatment

Diagnosis of diabetic kidney disease involves assessing urine albumin excretion and glomerular filtration rate (GFR) 44 . Early renal impairment is detected through albuminuria screening, while chronic albuminuria and GFR measurement aid in staging DKD severity 45 . Further diagnostic procedures include serum biomarkers, kidney biopsy, and renal imaging. Early identification and monitoring are crucial for prompt intervention and therapy to prevent DKD from progressing to end-stage renal disease.

Table 2 shows various diagnostic assessments used in the diagnosis of DKD, focusing on indicators of kidney function, damage, and overall metabolic control. These steps help in early detection, monitoring disease progression, and guiding treatment decisions. 46

Table 2: Various diagnostic assessments used in the diagnosis of DKD

Sr. no

Diagnostic Step

Description

A

Screening

1

Annual Screening

All patients with diabetes should undergo annual screening for kidney disease

2

Urinary Albumin Excretion

Measurement of urinary albumin-to-creatinine ratio (UACR) in a spot urine sample. Persistent albuminuria (>30 mg/g) indicates kidney damage 7

3

Glomerular Filtration Rate (GFR)

Calculation of estimated GFR (eGFR) using equations such as MDRD or CKD-EPI. Decreased eGFR (<60 mL/min/1.73m^2) indicates kidney damage

B

Diagnostic Confirmation

1

Confirmation of Albuminuria

Confirmatory testing with at least two out of three urine samples collected over 3-6 months

2

Measurement of Serum Creatinine

Measurement of serum creatinine levels to estimate GFR and assess kidney function

C

Additional Tests

1

Renal Imaging

Imaging studies such as ultrasound to assess kidney structure and identify anatomical abnormalities

2

Serum Biomarkers

Measurement of serum cystatin C or urinary biomarkers (e.g., KIM-1, NGAL) for additional information about kidney injury and prognosis

3

Renal Biopsy

In select cases, renal biopsy may be indicated to confirm diagnosis and guide treatment decisions

D

Evaluation of Complications

1

Cardiovascular Assessment

Assessment of cardiovascular risk factors (hypertension, dyslipidemia) given the high risk of cardiovascular disease in DKD

2

Screening for Other Complications

Regular screening for other diabetes-related complications such as retinopathy and neuropathy

E

Monitoring and Follow-up

1

Regular Monitoring

Regular monitoring of kidney function (eGFR, UACR), blood pressure, glycemic control, and other relevant parameters to guide treatment and assess disease progression

2

Multidisciplinary Care

Collaborative care involving primary care providers, endocrinologists, nephrologists, and other specialists for comprehensive management of DKD and associated comorbidities

Diagnosing diabetic kidney disease (DKD) involves UACR measurement and GFR assessment, which should be less than 60 ml/min per 1.73 m2. Even in cases of type 1 and type 2 diabetes, GFR decreases even when the ratio is within permissible limits. It is crucial for diabetics to check their creatinine levels annually. GFR can be calculated using formulas like the MDRD formula and the CKD-EPI equation. The American Diabetes Association recommends screening for nephropathy in all patients with type 2 diabetes and those with type 1 diabetes for more than five years.

Table 3: Tabular representation of the management and treatment of Diabetic Kidney Disease (DKD) 4748

Sr. no

Treatment

Description

Examples

1

Glycemic Control

Tight glycemic control to delay DKD progression

Metformin, Insulin, SGLT2 inhibitors

2

Blood Pressure Management

Use of RAAS blockers to reduce proteinuria and slow DKD progression

ACE Inhibitors (e.g., Lisinopril), ARBs (e.g., Losartan)

3

Lipid Management

Statin therapy to reduce cardiovascular risk in DKD

Atorvastatin, Rosuvastatin

4

Protein Restriction

Moderate protein restriction to reduce proteinuria

Dietary counseling

5

Sodium Restriction

Limiting sodium intake to manage hypertension and fluid retention

Dietary counseling

6

RAAS Blockade

Use of ACE inhibitors or ARBs to preserve renal function

Enalapril, Irbesartan

7

Anticoagulation Therapy

Consideration of anticoagulation to reduce thromboembolic risk

Enoxaparin, Apixaban

8

Antiplatelet Therapy

Use of antiplatelet agents to reduce cardiovascular risk

Aspirin, Clopidogrel

9

Lifestyle Modifications

Promotion of healthy lifestyle behaviors.

Diet, Exercise, Smoking cessation

10

Regular Monitoring

Monitoring kidney function, blood pressure, and glycemic control.

eGFR, UACR, Blood pressure

11

Referral to Nephrology

Consultation with nephrologist for comprehensive management.

Nephrologist appointment

Conclusion

In recent years, new treatments for DKD have emerged due to ongoing research into potential targets for prediction, follow-up, and prevention. Nevertheless, the integration of these indicators into clinical practice is currently undergoing development. Advancements in the development of new molecules and therapeutic approaches show promise for expanding the options available to doctors for more effective and individualised therapies in the future.

DKD is a medical disaster with high occurrence rates, inadequate detection methods, and a lack of new indicators for early diagnosis. Multinational and multicenter epidemiological investigations are necessary to validate the potential and suitability of novel plasma and urine biomarkers, which are proving effective for timely detection.

Acknowledgment

We thank Krescent Medical Research Pvt Ltd., for overall technical guidance during the preparation of this manuscript.

Financial support and sponsorship: Nil.

Conflicts of Interest: The authors declare no conflict of interest.

Software used: The figures were created using BioRender 1 and Canva 2 .

 

 

References

  1. Hoogeveen EK. The epidemiology of diabetic kidney diseaseKidney and Dialysis2022;2(3):433442. Available from: https://doi.org/10.3390/kidneydial2030038
  2. Haller B, Ulm K, Hapfelmeier A. A simulation study comparing different statistical approaches for the identification of predictive biomarkersComputational and Mathematical Methods in Medicine2019;2019:115. Available from: https://doi.org/10.1155/2019/7037230
  3. Khurana N, James S, Coughlan MT, Macisaac RJ, Ekinci EI. Novel therapies for kidney disease in people with diabetesJournal of Clinical Endocrinology & Metabolism2022;107(1):e1e24. Available from: https://doi.org/10.1210/clinem/dgab639
  4. Inker L, Coresh J, Levey A, Tonelli M, Muntner P. Estimated GFR, albuminuria, and complications of chronic kidney diseaseJournal of the American Society of Nephrology2011;22(12):23222331. Available from: https://doi.org/10.1681/asn.2010111181
  5. Picow E. Improving the identification and management of diabetic nephropathy in patients with diabetes in primary careJournal of the American Association of Nurse Practitioners2023;35(11):740746. Available from: https://doi.org/10.1097/jxx.0000000000000921
  6. Kondhalkar AA, Hawale DV, Jha RK, Anjankar A. To study the potential biomarkers for the early identification of DKD in vidharbha regionBioscience Biotechnology Research Communications2021;14(7):4246. Available from: http://dx.doi.org/10.21786/bbrc/14.7.10
  7. IDF Diabetes Atlas 2021 (10). International Diabetes Federation. 2021.
  8. Sigfrids FJ, Groop PH. Progression and regression of kidney disease in type 1 diabetesFrontiers in Nephrology2023;3:115. Available from: https://doi.org/10.3389/fneph.2023.1282818
  9. Han Y, Lee K, Saha A, Han J, Choi H, Noh M, et al. Specialized proresolving mediators for therapeutic interventions targeting metabolic and inflammatory disordersBiomolecules & Therapeutics2021;29(5):455464. Available from: https://doi.org/10.4062/biomolther.2021.094
  10. Yamazaki T, Mimura I, Tanaka T, Nangaku M. Treatment of diabetic kidney disease: current and futureDiabetes & Metabolism Journal2021;45(1):1126. Available from: https://doi.org/10.4093/dmj.2020.0217
  11. Deng Y, Li N, Wu Y, Wang M, Yang S, Zheng Y. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019Frontiers in Endocrinology2021;12:115. Available from: https://doi.org/10.3389/fendo.2021.672350
  12. Rico-Fontalvo J, Aroca-Martinez G, Daza-Arnedo R, Cabrales J, Yánez T, Cardona-Blanco M, et al. Novel biomarkers of diabetic kidney diseaseBiomolecules2023;13(4):113. Available from: https://doi.org/10.3390%2Fbiom13040633
  13. Tamay-Cach F, Quintana-Pérez J, Trujillo-Ferrara J, Cuevas-Hernández R, Valle-Mondragón L, García-Trejo E. A review of the impact of oxidative stress and some antioxidant therapies on renal damageRenal Failure2015;38(2):171175. Available from: https://doi.org/10.3109/0886022X.2015.1120097
  14. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidaseJournal of the American Society of Nephrology2003;14(8 Suppl 3):S227S232. Available from: https://doi.org/10.1097/01.asn.0000077407.90309.65
  15. Hu H, Liang W, Zhang Z, Liu Z, FC, Bao Y, et al. The utility of perirenal fat in determining the risk of onset and progression of diabetic kidney diseaseInternational Journal of Endocrinology2022;2022:110. Available from: https://doi.org/10.1155/2022/2550744
  16. Reznichenko A, Nair V, Eddy S, Tomilo M, Slidel T, Ju W, et al. Molecular Stratification of Chronic Kidney DiseasemedRxiv2021;p. 136. Available from: https://doi.org/10.1101/2021.09.09.21263234
  17. Reinhardt W, Mülling N, Behrendt S, Benson S, Dolff S, Führer D, et al. Association between albuminuria and thyroid function in patients with chronic kidney diseaseEndocrine2021;73(2):367373. Available from: https://doi.org/10.1007/s12020-021-02640-1
  18. Liao Y, Liao W, Liu J, Xu G, Zeng R. Assessment of the CKD-EPI equation to estimate glomerular filtration rate in adults from a chinese CKD populationJournal of International Medical Research2011;39(6):22732280. Available from: https://doi.org/10.1177/147323001103900624
  19. Beben T, Rifkin DE. GFR estimating equations and liver diseaseAdvances in Chronic Kidney Disease2015;22(5):337342. Available from: https://doi.org/10.1053%2Fj.ackd.2015.05.003
  20. Bostom AG, Kronenberg F, Ritz E. Predictive Performance of Renal Function Equations for Patients with Chronic Kidney Disease and Normal Serum Creatinine LevelsJournal of the American Society of Nephrology2002;13(8):21402144. Available from: https://dx.doi.org/10.1097/01.asn.0000022011.35035.f3
  21. Faubel S, Chawla LS, Chertow GM, Goldstein SL, Jaber BL, Liu KD. Ongoing Clinical Trials in AKIClinical Journal of the American Society of Nephrology2012;7(5):861873. Available from: https://dx.doi.org/10.2215/cjn.12191111
  22. Volpe M, Volpe R, Gallo G, Presta V, Tocci G, Folco E, et al. 2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive DocumentHigh Blood Pressure & Cardiovascular Prevention2017;24(3):313329. Available from: https://dx.doi.org/10.1007/s40292-017-0211-6
  23. Abdallah NH, Kamel MF, Abdelaziz A, Elkareem RMA. Urinary Retinol Binding Protein (RBP) Level as an early Biomarker of Diabetic Nephropathy in type 2 Diabetic PatientsEgyptian Journal of Medical Research2020;1(2):4960. Available from: https://dx.doi.org/10.21608/ejmr.2020.90106
  24. Bonventre JV. Kidney Injury Molecule‐1 (KIM‐1): A specific and sensitive biomarker of kidney injuryScandinavian Journal of Clinical and Laboratory Investigation2008;68(sup241):7883. Available from: https://dx.doi.org/10.1080/00365510802145059
  25. Lupusoru GE, Ailincai IG, Sorohan BM, Andronesi AG, Lupusoru M, Andronesi D, et al. Mo648 Serum soluble urokinase plasminogen activator receptor in patients with diabetic kidney diseaseNephrology Dialysis Transplantation2021;36(Supplement_1):1. Available from: https://dx.doi.org/10.1093/ndt/gfab094.0016
  26. Kamijo-Ikemori A, Sugaya T, Ichikawa D, Hoshino S, Matsui K, Yokoyama T, et al. Urinary liver type fatty acid binding protein in diabetic nephropathyClinica Chimica Acta2013;424:104108. Available from: https://dx.doi.org/10.1016/j.cca.2013.05.020
  27. Juretzko A, Steinbach A, Hannemann A, Endlich K, Endlich N, Friedrich N, et al. Urinary Angiotensinogen and Renin Excretion are Associated with Chronic Kidney DiseaseKidney and Blood Pressure Research2017;42(1):145155. Available from: https://dx.doi.org/10.1159/000474932
  28. Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 yearsKidney International2017;92(2):388396. Available from: https://dx.doi.org/10.1016/j.kint.2017.01.030
  29. Lecamwasam A, Ekinci E, Dwyer K, Saffery R. The identification of potential biomarkers of chronic kidney disease in individuals with diabetesKidney International Reports2019;4(7):1. Available from: https://doi.org/10.1016/j.ekir.2019.05.1100
  30. Ali SI, Morsy AA, Mohammed RA, Gelany HAE. Kim-1 and NGAL as biomarkers of nephropathy in type II diabetesInternational Journal of Advanced Research2018;6(2):14121417. Available from: http://dx.doi.org/10.21474/IJAR01/6571
  31. Perco P, Pena M, Heerspink H, Mayer G. Multimarker panels in diabetic kidney disease: the way to improved clinical trial design and clinical practicekidney International Reports2019;4(2):212221. Available from: https://doi.org/10.1016%2Fj.ekir.2018.12.001
  32. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort studyThe Lancet2012;380(9844):807814. Available from: https://dx.doi.org/10.1016/s0140-6736(12)60572-8
  33. Kourtidou C, Stangou M, Marinaki S, Tziomalos K. Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney DiseaseInternational Journal of Molecular Sciences2021;22(20):111. Available from: https://doi.org/10.3390%2Fijms222011196
  34. Hussain S, Jamali M, Habib A, Hussain S, Akhtar M, Najmi A. Diabetic kidney disease: an overview of prevalence, risk factors, and biomarkersClinical Epidemiology and Global Health2021;9:26. Available from: https://doi.org/10.1016/j.cegh.2020.05.016
  35. Gameil MA, Marzouk RE, Elsebaie AH, Eldeeb AAA. Albuminuria independently determines intact parathyroid hormone in diabetic nephropathy with micro-albuminuriaThe Egyptian Journal of Hospital Medicine2021;84(1):20522056. Available from: https://dx.doi.org/10.21608/ejhm.2021.180351
  36. Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injuryBlood Purification2010;29(4):357365. Available from: https://doi.org/10.1159/000309421
  37. Kumar GS, Sandhya S, Tejaswini T, Raghavendra B. A review on biomarkers for early diagnosis of diabetic kidney diseaseInternational Journal for Multidisciplinary Research2023;5(1):14. Available from: https://doi.org/10.36948/ijfmr.2023.v05i01.1345
  38. García-Carro C, Vergara A, Bermejo S, Azancot MA, Sánchez-Fructuoso AI, Nieta MDSdl, et al. How to assess diabetic kidney disease progression from albuminuria to GFRJournal of Clinical Medicine2021;10(11):113. Available from: https://doi.org/10.3390%2Fjcm10112505
  39. Erman A, Rahamimov R, Mashraki T, Levy-Drummer R, Winkler J, DI. The Urine Albumin-to-Creatinine Ratio: Assessment of Its Performance in the Renal Transplant Recipient PopulationClinical Journal of the American Society of Nephrology2011;6(4):892897. Available from: https://doi.org/10.2215%2FCJN.05280610
  40. Bukabau J, Yayo E, Gnionsahé A, Monnet D, Pottel H, Cavalier É, et al. Performance of creatinine- or cystatin c-based equations to estimate glomerular filtration rate in sub-saharan african populationsKidney International2019;95(5):11811189. Available from: https://doi.org/10.1016/j.kint.2018.11.045
  41. Sontrop JM, Garg AX, Li L, Gallo K, Schumann V, Winick-Ng J, et al. Consecutive first-morning urine samples to measure change in the albumin-to-creatinine ratio: a pilot study of a home urine collection protocolCanadian Journal of Kidney Health and Disease2016;3:18. Available from: https://doi.org/10.1186/s40697-016-0095-8
  42. Ebert N, Bevc S, Bökenkamp A, Gaillard F, Hornum M, Jager KJ, et al. Assessment of kidney function: clinical indications for measured gfrClinical Kidney Journal2021;14(8):18611870. Available from: https://doi.org/10.1093%2Fckj%2Fsfab042
  43. Looker HC, Mauer M, Nelson RG. Role of kidney biopsies for biomarker discovery in diabetic kidney diseaseAdvances in Chronic kidney Disease2018;25(2):192201. Available from: https://doi.org/10.1053%2Fj.ackd.2017.11.004
  44. Koyner JL, Vaidya VS, Bennett MR, Ma Q, Worcester E, Akhter SA, et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injuryClinical Journal of the American Society of Nephrology2010;5(12):21542165. Available from: https://doi.org/10.2215/cjn.00740110
  45. Roberts I, Mason P, Fogo A. The renal biopsy . In: Oxford Textbook of Clinical Nephrology. (pp. 142-160Oxford University Press. 2015.

DON'T MISS OUT!

Subscribe now for latest articles and news.